{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:43:38Z","timestamp":1788997418328,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Despite the impressive efficacy of chimeric antigen receptor (CAR) T-cell therapy (CART) in B-cell non-Hodgkin lymphomas, durable responses are uncommon. The histopathologic and molecular features associated with treatment failure are still largely unknown. Therefore, we have analyzed 19 sequential tumor samples from 9 patients, prior anti-CD19 CART (pre-CART) and at relapse (post-CART), using immunohistochemistry, fluorescence in situ hybridization, array comparative genomic hybridization, next-generation DNA and RNA sequencing, and genome-scale DNA methylation. The initial diagnosis was diffuse large B-cell lymphoma (n=6), double-hit high-grade B-cell lymphoma (n=1), and Burkitt lymphoma (n=2). Histopathologic features were mostly retained at relapse in 7\/9 patients, except the frequent loss of 1 or several B-cell markers. The remaining 2 cases (1 diffuse large B-cell lymphoma and 1 Burkitt lymphoma) displayed a dramatic phenotypic shift in post-CART tumors, with the drastic downfall of B-cell markers and emergence of T-cell or histiocytic markers, despite the persistence of identical clonal immunoglobulin gene rearrangements. The post-CART tumor with aberrant T-cell phenotype showed reduced mRNA expression of most B-cell genes with increased methylation of their promoter. Fluorescence in situ hybridization and comparative genomic hybridization showed global stability of chromosomal alterations in all paired samples, including 17p\/<jats:italic toggle=\"yes\">TP53<\/jats:italic> deletions. New pathogenic variants acquired in post-CART samples included mutations triggering the PI3K pathway (<jats:italic toggle=\"yes\">PIK3R1<\/jats:italic>, <jats:italic toggle=\"yes\">PIK3R2<\/jats:italic>, <jats:italic toggle=\"yes\">PIK3C2G<\/jats:italic>) or associated with tumor aggressiveness (<jats:italic toggle=\"yes\">KRAS<\/jats:italic>, <jats:italic toggle=\"yes\">INPP4B<\/jats:italic>, <jats:italic toggle=\"yes\">SF3B1<\/jats:italic>, <jats:italic toggle=\"yes\">SYNE1<\/jats:italic>, <jats:italic toggle=\"yes\">TBL1XR1<\/jats:italic>). These results indicate that CART-resistant B-cell non-Hodgkin lymphomas display genetic remodeling, which may result in profound dysregulation of B-cell differentiation. Acquired mutations in the PI3K and KRAS pathways suggest that some targeted therapies could be useful to overcome CART resistance.<\/jats:p>","DOI":"10.1097\/pas.0000000000001834","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T02:05:42Z","timestamp":1637373942000},"page":"742-753","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation"],"prefix":"10.1097","volume":"46","author":[{"given":"Camille","family":"Laurent","sequence":"first","affiliation":[{"name":"Department of Pathology, Cancer University Institute of Toulouse, CHU de Toulouse"},{"name":"INSERM, U1037, Research Center In Cancer of Toulouse, laboratoire d\u2019excellence TOUCAN, Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Syrykh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cancer University Institute of Toulouse, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Hamon","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ad\u00e9la\u00efde","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Guille","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Escudi\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cancer University Institute of Toulouse, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Jalowicki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cancer University Institute of Toulouse, CHU de Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Fina","sequence":"additional","affiliation":[{"name":"Department of Pathology and Neuropathology, APHM, CHU Timone, Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bardet","sequence":"additional","affiliation":[{"name":"Pathology and Tumor Immunology, Institut Paoli-Calmettes, Research Center in Cancer of Marseille, INSERM U1068, CNRS UMR7258, Aix-Marseille University, UM105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena\u00efg","family":"Mescam","sequence":"additional","affiliation":[{"name":"Pathology and Tumor Immunology, Institut Paoli-Calmettes, Research Center in Cancer of Marseille, INSERM U1068, CNRS UMR7258, Aix-Marseille University, UM105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry J.","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Pathology, Necker Hospital, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut of Gustave Roussy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[{"name":"Department of Pathology, CHU de Bordeaux, INSERM U1053, Bordeaux University, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Centre Hospitalier Lyon Sud, Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[{"name":"Hematology, Andr\u00e9 Mignot Hospital, Versailles"},{"name":"Paris-Saclay University, UVSQ, Inserm, \u00c9quipe \u201cExposome et H\u00e9r\u00e9dit\u00e9,\u201d CESP, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Birnbaum","sequence":"additional","affiliation":[{"name":"Predictive Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Pathology and Tumor Immunology, Institut Paoli-Calmettes, Research Center in Cancer of Marseille, INSERM U1068, CNRS UMR7258, Aix-Marseille University, UM105"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"R1-20250608","first-page":"175","article-title":"How can we engineer CAR T cells to overcome resistance?","volume":"15","author":"Glover","year":"2021","journal-title":"Biologics"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.17191","article-title":"CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before","volume":"193","author":"Ghilardi","year":"2021","journal-title":"Br J Haematol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR T cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.21037\/tcr.2016.08.15","article-title":"Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy","volume":"5","author":"Perna","year":"2016","journal-title":"Transl Cancer Res"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020005123","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12967-021-02925-z","article-title":"Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients","volume":"19","author":"Haderbache","year":"2021","journal-title":"J Transl Med"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-07-2536","article-title":"Integrated profiling of basal and luminal breast cancers","volume":"67","author":"Ad\u00e9la\u00efde","year":"2007","journal-title":"Cancer Res"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00277-019-03853-1","article-title":"Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy","volume":"99","author":"Maeshima","year":"2020","journal-title":"Ann Hematol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"E1928","DOI":"10.3390\/ijms19071928","article-title":"Molecular regulation of differentiation in early B-lymphocyte development","volume":"19","author":"Sigvardsson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1101\/gad.285536.116","article-title":"Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states","volume":"30","author":"Somasundaram","year":"2016","journal-title":"Genes Dev"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/modpathol.2017.177","article-title":"CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall","volume":"31","author":"Pan","year":"2018","journal-title":"Mod Pathol"},{"key":"R27-20250608","first-page":"8303571","article-title":"Blastoid variant mantle cell lymphoma expressing aberrant CD3 and CD10 with concurrent small lymphocytic lymphoma: establishment of a clonal relationship by B- and T-cell receptor gene rearrangements","volume":"2018","author":"Felten","year":"2018","journal-title":"Case Rep Hematol"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12185-019-02810-y","article-title":"Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression","volume":"111","author":"Tamura","year":"2020","journal-title":"Int J Hematol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nature06159","article-title":"Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors","volume":"449","author":"Cobaleda","year":"2007","journal-title":"Nature"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/44164","article-title":"Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors","volume":"401","author":"Rolink","year":"1999","journal-title":"Nature"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcancer.2017.09.008","article-title":"Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis","volume":"51","author":"Langstein","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PAS.0000000000001547","article-title":"Postchemotherapy histiocyte-rich pseudotumor mimicking residual lymphoma: a report of 11 cases correlating clinicopathologic and radiologic findings","volume":"45","author":"Fang","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41375-018-0215-9","article-title":"Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia","volume":"33","author":"Leeksma","year":"2019","journal-title":"Leukemia"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"551.e14","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"e0233058","DOI":"10.1371\/journal.pone.0233058","article-title":"Study of Caspase 8 mutation in oral cancer and adjacent precancer tissues and implication in progression","volume":"15","author":"Singh","year":"2020","journal-title":"PLoS ONE"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"88410","DOI":"10.18632\/oncotarget.11120","article-title":"ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy","volume":"8","author":"Yasukawa","year":"2017","journal-title":"Oncotarget"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/s12885-018-4701-2","article-title":"Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers","volume":"18","author":"Kordowski","year":"2018","journal-title":"BMC Cancer"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cell.2021.02.020","article-title":"An expanded universe of cancer targets","volume":"184","author":"Hahn","year":"2021","journal-title":"Cell"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41467-021-21736-w","article-title":"KRAS drives immune evasion in a genetic model of pancreatic cancer","volume":"12","author":"Ischenko","year":"2021","journal-title":"Nat Commun"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"1083.e6","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"947858","DOI":"10.1155\/2011\/947858","article-title":"PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors","volume":"2011","author":"Dituri","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:06:32Z","timestamp":1749416792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001834","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}